Terns Pharmaceuticals (TERN) has suddenly landed on many investors radar after reporting encouraging CARDINAL trial data for its CML pill, with major molecular response rates and cancer cell ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...
This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...
While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
In the second part of our interview with Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic ...
In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.
Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback